DISCOUNT-ZERTIFIKAT - STRATEC BIOMEDICAL Share Price

Certificat

DE000DJ1Z8F1

Market Closed - Deutsche Boerse AG 20:34:43 31/05/2024 BST
31.86 EUR +0.03% Intraday chart for DISCOUNT-ZERTIFIKAT - STRATEC BIOMEDICAL
1 month+0.73%
3 months+2.18%
Date Price Change
31/05/24 31.86 +0.03%
30/05/24 31.85 -.--%
29/05/24 31.85 -.--%
28/05/24 31.85 +0.03%
27/05/24 31.84 +0.03%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 08:34 pm

More quotes

Static data

Product typeCertificati Discount
Buy / SellCALL
Underlying STRATEC SE
Issuer DZ BANK
WKN DJ1Z8F
ISINDE000DJ1Z8F1
Date issued 30/05/2023
Maturity 21/06/2024 (20 Days)
Parity 1 : 1
Emission price 30.77
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 31.9
Lowest since issue 29.16

Company Profile

Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
Sector
-
More about the company

Ratings for Stratec SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Stratec SE

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
47.65 EUR
Average target price
42.33 EUR
Spread / Average Target
-11.16%
Consensus